228 related articles for article (PubMed ID: 24216282)
1. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.
Bihan K; Sauzay C; Goldwirt L; Charbonnier-Beaupel F; Hulot JS; Funck-Brentano C; Zahr N
Ther Drug Monit; 2015 Feb; 37(1):132-6. PubMed ID: 24977381
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
[TBL] [Abstract][Full Text] [Related]
4. Quantifying vemurafenib in dried blood spots using high-performance LC-MS/MS.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
Bioanalysis; 2014; 6(23):3215-24. PubMed ID: 25529888
[TBL] [Abstract][Full Text] [Related]
5. A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients.
Alvarez JC; Funck-Brentano E; Abe E; Etting I; Saiag P; Knapp A
J Pharm Biomed Anal; 2014 Aug; 97():29-32. PubMed ID: 24814993
[TBL] [Abstract][Full Text] [Related]
6. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Nijenhuis CM; Huitema AD; Marchetti S; Blank C; Haanen JB; van Thienen JV; Rosing H; Schellens JH; Beijnen JH
J Clin Pharmacol; 2016 Oct; 56(10):1307-12. PubMed ID: 26918324
[TBL] [Abstract][Full Text] [Related]
7. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM; Haverkate H; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jun; 125():270-9. PubMed ID: 27058232
[TBL] [Abstract][Full Text] [Related]
9. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E; Mercier T; Wagner AD; Homicsko K; Michielin O; Ellefsen-Lavoie K; Cagnon L; Diezi M; Buclin T; Widmer N; Csajka C; Decosterd L
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():124-136. PubMed ID: 29544202
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.
Herbrink M; Thijssen B; Hillebrand MJX; Rosing H; Schellens JHM; Nuijen B; Beijnen JH
J Pharm Biomed Anal; 2018 Jan; 148():259-264. PubMed ID: 29059615
[TBL] [Abstract][Full Text] [Related]
12. Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state.
Vikingsson S; Strömqvist M; Svedberg A; Hansson J; Höiom V; Gréen H
Biomed Chromatogr; 2016 Aug; 30(8):1234-9. PubMed ID: 26683023
[TBL] [Abstract][Full Text] [Related]
13. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Zhen Y; Thomas-Schoemann A; Sakji L; Boudou-Rouquette P; Dupin N; Mortier L; Vidal M; Goldwasser F; Blanchet B
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():93-7. PubMed ID: 23602929
[TBL] [Abstract][Full Text] [Related]
14. Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A; White-Koning M; Dupin N; Kramkimel N; Thomas-Schoemann A; Noé G; Chapuis N; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Pharmacol Res; 2016 Nov; 113(Pt A):709-718. PubMed ID: 27378568
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma.
Sakji-Dupré L; Le Rhun E; Templier C; Desmedt E; Blanchet B; Mortier L
Melanoma Res; 2015 Aug; 25(4):302-5. PubMed ID: 25933211
[TBL] [Abstract][Full Text] [Related]
16. Indacaterol determination in human urine: validation of a liquid-liquid extraction and liquid chromatography-tandem mass spectrometry analytical method.
Ammari WG; Al-Qadhi Z; Khalil M; Tayyem R; Qammaz S; Oriquat G; Basheti IA; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):202-10. PubMed ID: 25229261
[TBL] [Abstract][Full Text] [Related]
17. Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.
Funck-Brentano E; Alvarez JC; Longvert C; Abe E; Beauchet A; Funck-Brentano C; Saiag P
Ann Oncol; 2015 Jul; 26(7):1470-5. PubMed ID: 25899783
[TBL] [Abstract][Full Text] [Related]
18. Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.
Lanshoeft C; Heudi O; Leuthold LA; Schlotterbeck G; Elbast W; Picard F; Kretz O
Anal Bioanal Chem; 2014 Sep; 406(22):5413-23. PubMed ID: 24958346
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.
Herbrink M; de Vries N; Rosing H; Huitema ADR; Nuijen B; Schellens JHM; Beijnen JH
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29165815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
